Our study showed that HALP, NLR, and PLR values at various time points effectively predicted immunotherapy response in advanced NSCLC patients, where low HALP combined with high NLR and PLR values was associated with poor prognosis. The gene discussed is NAT10; the disease is non-small cell lung carcinoma.